TITLE

A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis

AUTHOR(S)
Elmunzer, B. J.; Waljee, A. K.; Elta, G. H.; Taylor, J. H.; Fehmi, S. M. A.; Higgins, P. B. A.
PUB. DATE
September 2008
SOURCE
Gut;Sep2008, Vol. 57 Issue 9, p1262
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Several pharmacological agents for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) have been studied. Clinical trials evaluating the protective effect of non-steroidal anti-inflammatory drugs (NSAIDs) have yielded inconclusive results. Aim: To perform a meta-analysis of studies evaluating the effect of prophylactic rectal NSAIDs on PEP. Methods: By searching Medline, Embase, meeting abstracts and bibliographies, two independent reviewers systematically identified prospective randomised controlled trials (RCTs) examining the effect of rectally administered prophylactic NSAIDs on the incidence of PEP pancreatitis. A meta-analysis of these clinical trials was performed. Results: Four RCTs, enrolling a total of 912 patients, have been published. Meta-analysis of these studies demonstrates a pooled relative risk for PEP after prophylactic administration of NSAIDs of 0.36 (95% Cl 0.22 to 0.60); patients who received NSAIDs in the periprocedural period were 64% less likely to develop pancreatitis and 90% less likely to develop moderate to severe pancreatitis. The pooled number needed to treat with NSAIDs to prevent one episode of pancreatitis is 15 patients. No adverse events attributable to the use of NSAIDs were reported in any of the clinical trials. Conclusion: In this meta-analysis, prophylactic NSAIDs were effective in preventing PEP. Widespread prophylactic administration of these agents may significantly reduce the incidence of PEP, resulting in major clinical and economic benefit. Given current scepticism regarding the efficacy of any prophylactic medication for ERCP, additional multicentre studies are needed for confirmation prior to widespread adoption of this strategy.
ACCESSION #
34310416

 

Related Articles

  • Can Rectal Diclofenac Prevent Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis? Lua, Guan; Muthukaruppan, Raman; Menon, Jayaram; Lua, Guan Way // Digestive Diseases & Sciences;Oct2015, Vol. 60 Issue 10, p3118 

    Background: Non steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the incidence of post endoscopic retrograde cholangiopancreatography pancreatitis (PEP). There were various trials using different routes and dosages of NSAIDs but meta-analysis revealed...

  • Rectal NSAIDs for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. Sun, Hong-Li; Han, Bing; Zhai, Hong-Peng; Cheng, Xin-Hua; Ma, Kai // Surgeon (Elsevier Science);Apr2014, Vol. 12 Issue 2, p141 

    Background and purpose Acute pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). We conducted a meta-analysis to evaluate the efficacy and safety of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP...

  • Chemoprevention of Post-ERCP Pancreatitis with Rectal NSAIDs: Does Poking Both Ends Justify the Means? Shah, Tilak; Zfass, Alvin; Schubert, Mitchell; Schubert, Mitchell L // Digestive Diseases & Sciences;Oct2015, Vol. 60 Issue 10, p2863 

    No abstract available.

  • A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. Elmunzer, B. Joseph; Scheiman, James M.; Lehman, Glen A.; Chak, Amitabh; Mosler, Patrick; Higgins, Peter D.R.; Hayward, Rodney A.; Romagnuolo, Joseph; Elta, Grace H.; Sherman, Stuart; Waljee, Akbar K.; Repaka, Aparna; Atkinson, Matthew R.; Cote, Gregory A.; Kwon, Richard S.; McHenry, Lee; Piraka, Cyrus R.; Wamsteker, Erik J.; Watkins, James L.; Korsnes, Sheryl J. // New England Journal of Medicine;4/12/2012, Vol. 366 Issue 15, p1414 

    Background: Preliminary research suggests that rectally administered nonsteroidal antiinflammatory drugs may reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). Methods: In this multicenter, randomized, placebo-controlled, double-blind clinical...

  • Effect of Diclofenac on the Levels of Lipoxin A4 and Resolvin D1 and E1 in the Post-ERCP Pancreatitis. Zhao, Xiao-wen; Bao, Jun-jun; Hu, Cui; Ding, Hao; Liu, Xiao-chang; Mei, Qiao; Xu, Jian-ming // Digestive Diseases & Sciences;Dec2014, Vol. 59 Issue 12, p2992 

    Objectives: Acute pancreatitis is one of the most common complications of endoscopic retrograde cholangiopancreatography (ERCP). Numerous studies have shown that administered nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the incidence of acute pancreatitis after ERCP. Little is known,...

  • Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. Minghua Zheng; Jianling Bai; Bosi Yuan; Feng Lin; Jie You; Mingqin Lu; Yuewen Gong; Yongping Chen // BMC Gastroenterology;2008, Vol. 8, Special section p1 

    Background: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography and benefit of pharmacological treatment is unclear. Although prophylactic use of corticosteroid for reduction of pancreatic injury after ERCP has been evaluated, discrepancy about...

  • Early ERCP for Gallstone Pancreatitis: For Whom and When? Behrns, Kevin E.; Ashley, Stan W.; Hunter, John G.; Carr-Locke, David // Journal of Gastrointestinal Surgery;Apr2008, Vol. 12 Issue 4, p629 

    The indications for early endoscopic retrograde cholangiopancreatography (ERCP) in gallstone pancreatitis are unclear, and the examination is often requested or performed without substantial supporting evidence. Several trials have been performed to determine the benefit of early ERCP in...

  • Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial. Andrade-Dávila, Víctor Fernando; Chávez-Tostado, Mariana; Dávalos-Cobián, Carlos; García-Correa, Jesús; Montaño-Loza, Alejandro; Fuentes-Orozco, Clotilde; Macías-Amezcua, Michel Dassaejv; García-Rentería, Jesús; Rendón-Félix, Jorge; Cortés-Lares, José Antonio; Ambriz-González, Gabriela; Cortés-Flores, Ana Olivia; del Socorro Alvarez-Villaseñor, Andrea; González-Ojeda, Alejandro // BMC Gastroenterology;Jul2015, Vol. 15 Issue 1, p1 

    Background: Acute pancreatitis is the most common major complication after endoscopic retrograde cholangiopancreatography (ERCP). Many drugs have been evaluated for prophylaxis, including nonsteroidal anti-inflammatory drugs (NSAIDs), which are potent inhibitors of phospholipase A2 and play a...

  • Use of Prophylactic Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis. Freeman, Martin L. // Gastroenterology & Hepatology;Jun2015, Vol. 11 Issue 6, p420 

    An interview with Martin L. Freeman, a professor of medicine at the University of Minnesota, is presented. Topics include the risk factors for post-endoscopic retrogade cholangiopancreatography (ERCP) development, early stent migration into the bowel, and the disadvantages of using prophylactic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics